Li et al. (2018) reported that Dioscin (0, 1.25, 2.5 and 5 μg/mL for 0, 6, 12 h) time- and dose-dependently inhibited proliferation and promoted apoptosis in RKO, HT-29 cells, which may be related to the activation of JNK/p38 MAPK mediated by ROS. Vivo experiments confirmed that (Tong et al., 2014) Dioscin (30, 60 mg/kg) decreased blood vessel density and inhibited tumor growth in C26 mouse tumor model. The gene discussed is MAPK8; the disease is neoplasm.